A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Drugmaker Pfizer’s fourth-quarter profit plunged 59 percent because of discontinued operations, restructuring and other charges, and generic competition continuing to bleed sales of former blockbuster ...

Pfizer will pay $94 million to resolve allegations that it used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex. The lawsuit, brought by 32 direct purchasers of ...

FDA approves a new Depo-Provera warning on meningioma risk as Pfizer faces lawsuits alleging delayed disclosure of brain ...

Revenue in 2026 will be $59.5 billion to $62.5 billion, roughly in line with Wall Street’s estimate, Pfizer said Tuesday in a ...

(Reuters) - Five big U.S. retailers filed an antitrust lawsuit against Pfizer Inc and India's Ranbaxy Laboratories Ltd on Thursday, accusing them of conspiring to delay sales of generic versions of ...

The pharmaceutical company updated its sales guidance for 2025, saying it now expects $62 billion in revenue for the year.

The generic version will be distributed to 95 low- and middle-income countries. The United Nations-backed Medicines Patent Pool announced Thursday it has signed an agreement with 35 companies around ...